155 related articles for article (PubMed ID: 36278394)
1. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B
Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394
[TBL] [Abstract][Full Text] [Related]
2. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
[TBL] [Abstract][Full Text] [Related]
3. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
[TBL] [Abstract][Full Text] [Related]
4. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.
Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B
Ther Adv Neurol Disord; 2021; 14():17562864211058298. PubMed ID: 34899987
[TBL] [Abstract][Full Text] [Related]
5. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
6. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
7. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
Neurodegener Dis Manag; 2022 Feb; 12(1):1-7. PubMed ID: 35019731
[TBL] [Abstract][Full Text] [Related]
8. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
9. Expert opinion on the use of cladribine tablets in clinical practice.
Sørensen PS; Centonze D; Giovannoni G; Montalban X; Selchen D; Vermersch P; Wiendl H; Yamout B; Salloukh H; Rieckmann P
Ther Adv Neurol Disord; 2020; 13():1756286420935019. PubMed ID: 32636933
[TBL] [Abstract][Full Text] [Related]
10. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
[TBL] [Abstract][Full Text] [Related]
11. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
[TBL] [Abstract][Full Text] [Related]
12. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.
Brill L; Rechtman A; Shifrin A; Rozenberg A; Afanasiev S; Zveik O; Haham N; Levin N; Vaknin-Dembinsky A
Mult Scler Relat Disord; 2022 Jul; 63():103863. PubMed ID: 35667316
[TBL] [Abstract][Full Text] [Related]
14. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
[TBL] [Abstract][Full Text] [Related]
15. Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group Viewpoint.
Petrou P; Achiron A; Cohen EG; Garty M; Magalashvili D; Karmon Y; Milo R; Regev K; Vaknin-Dembinsky A; Wilf-Yarkoni A; Karussis D
J Neurol; 2023 Nov; 270(11):5188-5195. PubMed ID: 37436562
[TBL] [Abstract][Full Text] [Related]
16. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals.
Shephard A; Kolaczkowski L; Barker N; Nahal D; Oreja-Guevara C; Reyes S; Gray H; Salloukh H; Giovannoni G
Neurol Ther; 2024 May; ():. PubMed ID: 38760637
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
18. Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.
Moiola L; Riva A; Nicoletti F; Uccelli A; Salvetti M; Battistini L; Furlan R
Curr Neuropharmacol; 2022; 20(10):1811-1815. PubMed ID: 34923946
[TBL] [Abstract][Full Text] [Related]
19. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
20. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
